CRVS CORVUS PHARMACEUTICALS

Health Care · Russell 2000

Next earnings: not announced yet

What 10 analyst firms say about CORVUS PHARMACEUTICALS: their latest ratings, price targets and how far the stock is from them. How it works

10.54 USD+0.81 (+8.32%) today

Price as of 6 Nov 16:00 ET

Analyst window: Latest analyst report within last 1 year

Analyst view · last 1Y

+210.4%to the avg target 32.71 USD+22.17 USD

Buy 7 · Hold 1 · Sell 0

8 rated views · 10 analyst/firm records · 10 firms

Latest report29 Oct 2026avg report date 2 Jun

Target rangePrice is below every target

now 10.54

Radar score

Russell 2000 · Top Picks · 6MBelow the Radar threshold of 8070
Russell 2000 · Safest consensus · 6MBelow the Radar threshold of 8045

Recent analyst activity · last 90 days

Our tracked history has 3 reports on CRVS from 3 analyst firms in the last 90 days (10 firms in the past year).

Comparing each firm's latest target with its previous one: 1 lowered it.

Latest observed target change: Mizuho lowered its target from $30.00 (set 12 Jun 2026) to $27.00 on 29 Oct 2026.

Last 1 year. Latest opinion per identifiable analyst within the last 1 year. BUY / HOLD / SELL each count one current analyst vote; unnamed firm records are a fallback.

Firm	Analyst	Latest rating	Report date	Latest target (USD)
Barclays	Etzer Darout	Buy	7 Aug 2026	28.00 USD
Cantor Fitzgerald	Li Watsek	Buy	16 Sep 2026	—
Goldman Sachs	Paul Choi	Buy	17 Apr 2026	40.00 USD
H.C. Wainwright	Sean Lee	Buy	15 May 2026	27.00 USD
Jefferies	Roger Song	Buy	22 Jan 2026	42.00 USD
Ladenburg Thalmann	Kevin M Degeeter	Buy	30 Jul 2026	32.00 USD
Mizuho	Graig Suvannavejh	ConflictConflicting reports · excluded	29 Oct 2026	27.00 USD
Oppenheimer	Jeff Jones	Buy	13 Mar 2026	33.00 USD
Weiss Ratings	Unnamed analyst	—	26 Oct 2026	—
Data feed RESEARCH	Research Team	Hold	15 Jun 2026	—

Partial coverage · checked 6 Nov (6 Nov 2026, 06:14 ET). Some research records could not be refreshed. Cached records retained. Prices stream live during the US session; otherwise stored prices delayed about 15 minutes. A summary of analyst opinion, not investment advice.